Watch Tuesday: MFN, tariffs and a DTC push — Inside Trump’s drug-pricing reset

The final session of MJH Life Sciences’ three-part webinar series on President Trump’s “Most Favored Nation” (MFN) drug-pricing will be held Tuesday, Nov. 4, at 7 p.m. ET. This installment zeroes in on how MFN interacts with new trade tactics and direct-to-consumer (DTC) distribution — and what that mix could mean for prescribers, patients and practice revenue.

Register here for “Most Favored Nation Order: How Trump Is Disrupting Pharma: Exploring the Impacts of MFN, Tariffs and DTC on Drug Markets.”

The webinar looks at how MFN could be operationalized alongside emerging DTC channels and potential tariffs — and what those moving parts mean in day-to-day terms:

Questions we'll answer:

• What would an MFN style benchmark do to acquisition costs and reimbursement mechanics?
• Where could mandatory payment models like GLOBE and GUARD fit, and how might they change prescribing and purchasing workflows?
• How could a shift toward DTC distribution affect prior authorizations, cash pay conversations and patient counseling at the point of care?
• What would this mean for 340B participants, specialty-drug flows and buy-and-bill margins?

Meet the panel

Moderator: Ronald W. Lanton III, Esq. — Partner at Lanton Law, Lantonhas spent more than 25 years working at the intersection of health care law and government affairs at the municipal, state and federal levels.

Neal Masia, Ph.D. — Co‑founder and CEO of EntityRisk; founder of Health Capital Group; adjunct professor of management and economics at Columbia University. Masia brings a market-access lens from years in biopharma leadership.

Stacie B. Dusetzina, Ph.D. — Professor of health policy and Ingram professor of Cancer Research at Vanderbilt University School of Medicine. Dusetzina focuses on how policy and pricing shape patient access.

Lindsay Greenleaf, J.D., MBA — Head of policy, research and analysis at ADVI Health. Greenleaf translates legislation and regulation into commercialization and access strategies across pharma, devices, diagnostics and physician practices.

Why this matters for practices

For independent practices and health‑system clinics alike, small policy shifts can mean big operational change.

MFN concepts, if applied, could alter acquisition prices, payer contracts and formulary dynamics. And any move toward DTC channels raises new questions about care coordination, affordability conversations and how you help patients navigate coverage versus cash‑pay options.

The panel will focus on concrete implications — how to prepare budgets, set expectations with staff and talk with patients about access and out‑of‑pocket costs.

Catch up on parts one and two

Missed the first two sessions? Stream the full recordings and find key takeaways:

1. Part 1 (Sept. 10): Key takeaways on policy uncertainty, patient access, and how manufacturers might respond.
   1. Register and watch here.
2. Part 2 (Oct. 8): ‘Coercive and chaotic:’ 7 takeaways on Trump’s most-favored nation drug pricing plan for physicians.
   1. Register and watch here.

How to join

Date: Tuesday, Nov. 4, 2025

Time: 7:00 p.m. ET

Topic: Most Favored Nation Order: How Trump Is Disrupting Pharma: Exploring the Impacts of MFN, Tariffs and DTC on Drug Markets

Register: Click here to reserve your seat now.

This series is produced by MJH Life Sciences® in collaboration with our sister health care brands, including The American Journal of Managed Care®, Chief Healthcare Executive®, Drug Topics®, HCPLive®, Managed Healthcare Executive®, Medical Economics®, OncLive®, Pharmaceutical Commerce®, Pharmaceutical Executive®, and Pharmacy Times®.